Related Experiment Video
Updated: Jun 19, 2026
04:33
Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
Published on: April 26, 2024
Major depression, cognitive dysfunction and Alzheimer's disease: is there a link?
Annerieke S R Sierksma1, Daniel L A van den Hove, Harry W M Steinbusch
1Department of Neuroscience, Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Maastricht University, The Netherlands. a.sierksma@np.unimaas.nl
European Journal of Pharmacology
|October 20, 2009
Summary
Major depression (MD) is linked to Alzheimer's disease (AD) risk. Altered hypothalamic-pituitary-adrenal (HPA) axis and serotonin systems may connect MD and AD neuropathology, impacting cognition.
Area of Science:
- Neuroscience
- Psychiatry
- Pathology
Background:
- Major depression (MD) involves mood and cognitive alterations, with neuropathology in the limbic system.
- Hypothalamic-pituitary-adrenal (HPA) axis overdrive and reduced serotonin are implicated in MD pathogenesis.
- Interactions between the HPA axis and serotonergic system affect neural networks and depressive symptoms.
Purpose of the Study:
- To explore the potential link between major depression (MD) and Alzheimer's disease (AD).
- To investigate the role of the HPA axis and serotonergic system in the comorbidity of MD and AD.
Main Methods:
- Review of existing literature on the neuropathology of major depression.
- Analysis of the interaction between the HPA axis and serotonergic system in mood disorders.
- Examination of epidemiological data suggesting MD as an AD risk factor.
Main Results:
- MD is associated with cognitive decline and increased AD risk, with higher AD-related neuropathology.
- HPA axis and serotonergic system dysregulation may contribute to cognitive impairment in MD patients.
- These systems offer a potential biological link between MD and AD pathogenesis.
Conclusions:
- The HPA axis and serotonergic system are critically involved in both major depression and Alzheimer's disease.
- Understanding their interactive role may lead to novel therapeutic strategies for both conditions.
- Further research into these interconnected systems is crucial for advancing treatment for depression and dementia.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.